Highest-materiality recent filing
Stockholders approved assignment for benefit of creditors and voluntary dissolution at July 21 special meeting; 13.3M votes for, 100.9K against.
Vicarious Surgical CFO Sarah Romano resigns, effective July 22, 2026
CFO Sarah Romano notified board of resignation on June 24, 2026.
Vicarious Surgical shareholders approve reverse stock split at ratio of 1:2 to 1:30
Over 11.8M votes in favor, 49,675 against, 3,430 abstentions at April 8 special meeting.
Vicarious Surgical reports Q4 net loss $10.5M; NYSE delisting, now on OTCID
Q4 GAAP net loss $10.5M ($1.57/sh) vs $13.9M ($2.36/sh) YoY; FY2025 net loss $50.2M ($8.19/sh) vs $63.2M ($10.74/sh) YoY.
Vicarious Surgical NYSE delisting; President and CTO take salary cuts
NYSE commenced delisting proceedings on March 3, 2026; stock now quoted on OTC under RBOT.
Vicarious Surgical receives NYSE delisting notice; trading suspended, moves to OTCID
NYSE notified Vicarious Surgical on Mar 3, 2026 of delisting for falling below $15M avg mkt cap over 30 trading days.
Vicarious Surgical amends CEO severance, enters CFO severance agreement
CEO Stephen From severance without cause: 1 yr base salary + pro-rata bonus + 12 mos COBRA.
Vicarious Surgical shareholders approve exercise of Oct 2025 warrants for 2.3M shares
Special meeting held Jan 9, 2026; quorum of 78.18% of total voting power present.
Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants
FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.
Vicarious Surgical cuts 2025 cash burn outlook to ~$45M, improves by $5M
Full-year 2025 cash burn guidance improved to ~$45M from prior $50M, reflecting cost management.
Vicarious Surgical reports Q3 2025 net loss of $11.1M, down from $17.1M year-over-year
Total operating expenses fell 35% to $11.5M from $17.8M in Q3 2024
Vicarious Surgical prices $5.9M registered direct offering and private placement at $5.10/unit
Offering comprises 1,150,000 shares (or pre-funded warrants) and Series A & B warrants for up to 2,300,000 shares at $5.10 exercise price.
Vicarious Surgical appoints Joseph Doherty as Chairman of the Board
Doherty appointed Chairman effective Sept 25, 2025; he joined the Board in June 2025.
Controlled builds completed in April and August 2025 under full QMS, demonstrating reproducibility and scalability.
Director Donald Tang resigns; Victoria Carr-Brendel joins audit committee
Donald Tang resigned from the board effective September 12, 2025, not due to any disagreement.
First build under control completed April 2025; second build completed August 2025 demonstrating scalability.
Vicarious Surgical Q2 net loss narrows to $13.2M; CEO transition to Stephen From
GAAP net loss of $13.2M ($2.23/share) vs. $15.2M ($2.59/share) in Q2 2024.
Vicarious Surgical appoints Stephen From as CEO, Adam Sachs becomes President
Stephen From appointed CEO effective Aug 7, 2025; also joins Board.
Vicarious Surgical's NYSE compliance plan accepted; auditor changed to Cherry Bekaert
NYSE accepted compliance plan to regain $50M min market cap within 18 months; RBOT now trades with '.BC' indicator.
Vicarious Surgical elects Fuad Ahmad and Joseph Doherty to board; Ric Fulop departs
Fuad Ahmad (former CFO of Iridex, Mitek, Vaxart) and Joseph Doherty (CEO Worcester City Campus, former Olympus/J&J) elected at annual meeting.
Vicarious Surgical Q1 2025: GAAP net loss $15.4M; FY cash burn guided ~$50M
GAAP net loss $15.4M ($2.60/shr) vs $17.0M ($2.90) Q1 2024; adjusted net loss $15.3M ($2.58/shr).
Vicarious Surgical receives NYSE delisting notice for low market cap and equity
30-day avg market cap ~$47.4M and stockholders' equity $46.7M as of Dec 31, 2024.
Vicarious Surgical President Randy Clark resigns, appointed to Board effective April 25
President Randy Clark will resign effective April 25, 2025, and be appointed to the Board pending conflict checks.
FY2024 GAAP net loss $63.2M ($10.74/share), adjusted net loss $63.3M ($10.75/share); Q4 GAAP net loss $13.9M.
Vicarious Surgical Appoints Sarah Romano as CFO Effective April 1, 2025
Sarah Romano named CFO and Treasurer, effective April 1, 2025; succeeds prior CFO? Not disclosed.
COO John Mazzola to retire April 1, 2025; responsibilities to President Randy Clark
John Mazzola to retire as COO effective April 1, 2025, after nearly 40 years in healthcare.
Vicarious Surgical enters consulting agreement with former CFO William Kelly through 2028
William Kelly departed as CFO; consulting from Jan 2, 2025 to Dec 31, 2028.
Vicarious Surgical CFO William Kelly resigns effective Jan 2, 2025; succession search underway
William Kelly steps down as CFO after nearly 4 years (since Jan 2021) to pursue other opportunities.
Vicarious Surgical Q3 net loss $17.1M; cash $60.9M; on track for system milestone
GAAP net loss of $17.1M ($2.90/share); adjusted net loss $17.0M ($2.87/share), improved from $20.4M loss YoY.
Vicarious Surgical Q2 net loss $15.2M; cash burn $10.9M, reiterates FY2024 ~$50M
GAAP net loss $15.2M ($2.59/sh) vs $15.3M ($3.62/sh) in Q2 2023; adjusted net loss $16.8M ($2.86/sh).
Vicarious Surgical shareholders approve 1-for-30 reverse stock split, effective June 12, 2024
Shareholders approved reverse stock split at ratio of 1-for-30 effective June 12, 2024.
Vicarious Surgical announces 1-for-30 reverse stock split to comply with NYSE minimum share price
Reverse split ratio set at 1-for-30, approved by shareholders at June 10, 2024 annual meeting.
Vicarious Surgical reports Q1 2024 net loss of $17.0M; cash burn guidance unchanged at $50M
GAAP net loss $17.0M ($0.10/sh) vs $26.9M ($0.21) YoY; adjusted net loss $15.1M ($0.09).
Executive Chairman David Styka resigns from Vicarious Surgical board, effective Feb 29, 2024
David Styka notified Board on Feb 27 of his resignation as executive chairman and director, effective Feb 29.
Vicarious Surgical Q4 2023 GAAP net loss $13.1M; 2024 cash burn guided ~$50M
Q4 2023 GAAP net loss $13.1M ($0.06/sh); adjusted net loss $14.6M ($0.07/sh), improving from $19.9M ($0.16/sh) in Q4 2022.
Vicarious Surgical appoints Randy Clark as President; Adam Sachs remains CEO
Clark appointed President effective Jan 29, 2024; Sachs steps down as President, continues as CEO.
Vicarious Surgical Q3 loss $0.10 GAAP, delays system build to Fall 2024, De Novo to 2026
GAAP net loss $15.7M ($0.10/sh); adjusted net loss $20.4M ($0.12/sh).
Vicarious Surgical receives NYSE non-compliance notice for share price below $1.00
Received NYSE notice on Sept 20, 2023 that average closing price of Class A common stock was below $1.00 over 30 trading days.
Vicarious Surgical prices $45M public offering of 45M shares at $1.00 per share
Offering of 45,000,000 shares at $1.00/share; gross proceeds ~$45M; net ~$42M.
Vicarious Surgical Q2 2023 net loss $15.3M; expects first human procedure mid-2024
GAAP net loss $15.3M ($0.12/sh) vs $1.5M ($0.01/sh) YoY; adjusted net loss $20.4M ($0.16/sh).
Vicarious Surgical updates corporate presentation, targeting 2025 launch vs $150B market
$150B addressable abdominal market; 96% of procedures still manual per company estimates.
Stockholders approved amendment to 2021 Equity Incentive Plan increasing shares available by 6,970,817.
Vicarious Surgical promotes John Mazzola to newly created COO role
John Mazzola, previously SVP of Operations since March 2022, appointed COO effective May 18, 2023.
Vicarious Surgical Q1 net loss $26.9M; cash burn guidance $55-65M for FY 2023
GAAP net loss of $26.9M ($0.21/share) vs prior-year net income of $42.5M ($0.35 basic EPS).
Vicarious Surgical posts Q4 adj. loss $19.9M; FY 2022 cash burn $67M; guides FY 2023 burn $55-65M
Q4 2022 adjusted net loss $19.9M ($0.16 loss per share) vs $17.8M ($0.15 loss) in Q4 2021.
Vicarious Surgical appoints Victoria Carr-Brendel to board; Phil Liang resigns
Victoria Carr-Brendel, Ph.D., appointed to board effective Jan 23, 2023; deemed independent under NYSE rules.
Vicarious Surgical Q3 2022 net loss $24.7M; cash burn $14.5M
GAAP net loss $24.7M ($0.20/sh); adjusted net loss $21.7M ($0.18/sh) vs $45.1M ($0.49) last year.
Two directors resign from Vicarious Surgical; Beverly Huss appointed to Board and Audit Committee
Samir Kaul and Dror Berman resigned from Vicarious Surgical Board effective Oct 18; resignation not due to any disagreement.
Vicarious Surgical schedules Beta 2 robot demo day for Dec 6, 2022
Hosts Demonstration Day of Beta 2 surgical robot prototype at Waltham, MA headquarters.
Vicarious Surgical Q2 2022: adjusted net loss $19.1M, operating expenses up 189% YoY
Operating expenses of $19.1M for Q2 2022, up from $6.6M in Q2 2021; R&D $10.1M, G&A $7.8M, S&M $1.3M.
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.
the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.
the Company terminated the employment of each of Stephen From, the Company’s Chief Executive Officer, Adam Sachs, the Company’s President, Sammy Khalifa, the Company’s Chief Technology Officer, and Dr. Barry Greene, the Company’s Chief Medical Officer, effective as of the close of business on July 21, 2026.
each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the “SEC”).
On June 24, 2026, Sarah Romano notified the Board of Directors of her resignation as Chief Financial Officer of the Company, effective July 22, 2026, or such later date as may be mutually agreed upon by the Company and Ms. Romano.
Max materiality 1.00 · Median 0.60 · Most common event leadership